Audience
GLP-1 Considerers panel (US)
GLP-1 Considerers (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.
What did the GLP-1 Considerers panel say?
- #
65.5%
65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. — When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
base 139
- #
70.8%
70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). — GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
base 137
What has Brox published on glp-1 considerers panel (us)?Newest first
-
When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
65.5% 65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. (base 139)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read
What do people ask about glp-1 considerers panel (us)?
- When a health plan drops GLP-1 weight-loss coverage, what do people considering the drug do instead?
- When a health plan drops GLP-1 weight-loss coverage, 65.5% of US GLP-1 considerers would turn to diet and exercise or put treatment off rather than take any medicine, and only 11.5% would pay a drug maker's $350 to $500 cash price (n=139, October 2026).Read the insight
- What would make someone considering a GLP-1 weight-loss medication actually start?
- The monthly cost is the main thing holding back 70.8% of US adults considering a GLP-1 weight-loss medication who have never taken one (n=137, September 2026), and without insurance only 2.2% would be likely to start at $499 a month against 53.3% at $49.Read the insight
Other audiences
- Anime Fans (US) 4
- Brox HNWI (US) 8
- Casual dining and restaurants (US) 2
- E-commerce (US) 7
- Finance (US) 5
- G.B. nat. rep. (GB) 14
- GLP-1 (US) 1
- GLP-1 Past Users (US) 3
- Groceries (US) 3
- HCP (US) 10
- HCP Dermatologists (US) 4
- HCP Other (Non-Derm) (US) 2
- Healthcare (US) 10
- Healthcare Professionals (US) 1
- HNWI (VC/Tech) (US) 3
- Insurance (US) 15
- Investing (US) 1
- Japan nat. rep. (JP) 1
- Music (US) 1
- Streaming (JP) 1
- Streaming (US) 16
- Streaming (TR) 1
- Streaming - Custom (US) 2
- Tech (US) 5
- Tech (GB) 1
- Travel (US) 6
- TV & Social Media (JP) 1
- U.S. nat. rep. (US) 102
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai